Systemic Mesenchymal Stromal Cell Transplantation Prevents Functional Bone Loss in a Mouse Model of Age-Related Osteoporosis

This study shows that a single dose of minimally expanded mesenchymal stromal cells (MSCs) injected systemically into a mouse model of human age-related osteoporosis display long-term engraftment and prevent the decline in bone formation, bone quality, and microarchitectural competence. This work adds to a growing body of evidence suggesting that the decline of MSCs associated with age-related osteoporosis is a major transformative event in the progression of the disease. Furthermore, it establishes proof of concept that MSC transplantation may be a viable therapeutic strategy to treat or prevent human age-related osteoporosis.

Source: Stem Cells Translational Medicine - April 17, 2016 Category: Stem Cells Authors: Kiernan, J., Hu, S., Grynpas, M. D., Davies, J. E., Stanford, W. L. Tags: Tissue Engineering and Regenerative Medicine, Mesenchymal Stem Cells Source Type: research